Andreas Edsfeldt1, Pontus Dunér2, Marcus Ståhlman2, Ines G Mollet2, Giuseppe Asciutto2, Helena Grufman2, Mihaela Nitulescu2, Ana Flor Persson2, Rachel M Fisher2, Olle Melander2, Marju Orho-Melander2, Jan Borén2, Jan Nilsson2, Isabel Gonçalves2. 1. From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J.B.); Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Solna, Sweden (R.M.F.); and Department of Clinical Sciences Malmö, Clinical Research Center, Lund University, Malmö, Sweden (I.G.M., O.M., M.O.-M.). Andreas.Edsfeldt@med.lu.se. 2. From the Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Malmö, Sweden (A.E., P.D., G.A., H.G., M.N., A.F.P., J.N., I.G.); Vascular Centre Malmö-Lund, Skåne, University Hospital, Malmö, Sweden (G.A.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., H.G., A.F.P., I.G.); Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska University Hospital University, Gothenburg, Sweden (M.S., J.B.); Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Solna, Sweden (R.M.F.); and Department of Clinical Sciences Malmö, Clinical Research Center, Lund University, Malmö, Sweden (I.G.M., O.M., M.O.-M.).
Abstract
OBJECTIVE: Lipids are central to the development of atherosclerotic plaques. Specifically, which lipids are culprits remains controversial, and promising targets have failed in clinical studies. Sphingolipids are bioactive lipids present in atherosclerotic plaques, and they have been suggested to have both proatherogenic and antiatherogenic. However, the biological effects of these lipids remain unknown in the human atherosclerotic plaque. The aim of this study was to assess plaque levels of sphingolipids and investigate their potential association with and contribution to plaque vulnerability. APPROACH AND RESULTS: Glucosylceramide, lactosylceramide, ceramide, dihydroceramide, sphingomyelin, and sphingosine-1-phosphate were analyzed in homogenates from 200 human carotid plaques using mass spectrometry. Inflammatory activity was determined by analyzing plaque levels of cytokines and plaque histology. Caspase-3 was analyzed by ELISA technique. Expression of regulatory enzymes was analyzed with RNA sequencing. Human coronary artery smooth muscle cells were used to analyze the potential role of the 6 sphingolipids as inducers of plaque inflammation and cellular apoptosis in vitro. All sphingolipids were increased in plaques associated with symptoms and correlated with inflammatory cytokines. All sphingolipids, except sphingosine-1-phosphate, also correlated with histological markers of plaque instability. Lactosylceramide, ceramide, sphingomyelin, and sphingosine-1-phosphate correlated with caspase-3 activity. In vitro experiments revealed that glucosylceramide, lactosylceramide, and ceramide induced cellular apoptosis. All analyzed sphingolipids induced an inflammatory response in human coronary artery smooth muscle cells. CONCLUSIONS: This study shows for the first time that sphingolipids and particularly glucosylceramide are associated with and are possible inducers of plaque inflammation and instability, pointing to sphingolipid metabolic pathways as possible novel therapeutic targets.
OBJECTIVE:Lipids are central to the development of atherosclerotic plaques. Specifically, which lipids are culprits remains controversial, and promising targets have failed in clinical studies. Sphingolipids are bioactive lipids present in atherosclerotic plaques, and they have been suggested to have both proatherogenic and antiatherogenic. However, the biological effects of these lipids remain unknown in the humanatherosclerotic plaque. The aim of this study was to assess plaque levels of sphingolipids and investigate their potential association with and contribution to plaque vulnerability. APPROACH AND RESULTS:Glucosylceramide, lactosylceramide, ceramide, dihydroceramide, sphingomyelin, and sphingosine-1-phosphate were analyzed in homogenates from 200 human carotid plaques using mass spectrometry. Inflammatory activity was determined by analyzing plaque levels of cytokines and plaque histology. Caspase-3 was analyzed by ELISA technique. Expression of regulatory enzymes was analyzed with RNA sequencing. Human coronary artery smooth muscle cells were used to analyze the potential role of the 6 sphingolipids as inducers of plaque inflammation and cellular apoptosis in vitro. All sphingolipids were increased in plaques associated with symptoms and correlated with inflammatory cytokines. All sphingolipids, except sphingosine-1-phosphate, also correlated with histological markers of plaque instability. Lactosylceramide, ceramide, sphingomyelin, and sphingosine-1-phosphate correlated with caspase-3 activity. In vitro experiments revealed that glucosylceramide, lactosylceramide, and ceramide induced cellular apoptosis. All analyzed sphingolipids induced an inflammatory response in human coronary artery smooth muscle cells. CONCLUSIONS: This study shows for the first time that sphingolipids and particularly glucosylceramide are associated with and are possible inducers of plaque inflammation and instability, pointing to sphingolipid metabolic pathways as possible novel therapeutic targets.
Authors: Gayan S De Silva; Kshitij Desai; Malik Darwech; Uzma Naim; Xiaohua Jin; Sangeeta Adak; Nikolai Harroun; Luis A Sanchez; Clay F Semenkovich; Mohamed A Zayed Journal: Atherosclerosis Date: 2019-05-30 Impact factor: 5.162
Authors: Ruth R Magaye; Feby Savira; Yue Hua; Darren J Kelly; Christopher Reid; Bernard Flynn; Danny Liew; Bing H Wang Journal: Cell Mol Life Sci Date: 2018-12-06 Impact factor: 9.261
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2018-10 Impact factor: 8.311